Fintel · Nov 5, 2026
AD
NYSE · ADCT
ADC Therapeutics S.A.
Healthcare · Biotechnology
$1.58
Up+$0.09 (+5.70%)
Updated Nov 9, 2026, 10:04 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 507.9M
- P/E ratio
- -3.35
- Dividend yield
- 0.00%
- 52-week range
- $0.78 – $4.98
- Volume
- 823K
- Avg. volume
- 1.16M
Price performance · ADCT
ADCT price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
ADCT closed at $1.58 after 20 trading sessions, down 15.05% for the selected period.
- Last close
- $1.58
- Period change
- -15.05%
- Period low
- $1.40
- Period high
- $1.86
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $1.63 | $1.6397 | $1.515 | $1.58 | 823K |
| Nov 5, 2026 | $1.73 | $1.74 | $1.61 | $1.64 | 1.72M |
| Nov 4, 2026 | $1.61 | $1.865 | $1.61 | $1.72 | 4.3M |
| Nov 3, 2026 | $1.58 | $1.66 | $1.53 | $1.55 | 865.89K |
| Nov 2, 2026 | $1.58 | $1.675 | $1.50 | $1.54 | 1.07M |
| Oct 30, 2026 | $1.49 | $1.54 | $1.43 | $1.53 | 1.18M |
| Oct 29, 2026 | $1.67 | $1.70 | $1.49 | $1.49 | 899.75K |
| Oct 28, 2026 | $1.59 | $1.63 | $1.545 | $1.62 | 607.77K |
| Oct 27, 2026 | $1.49 | $1.60 | $1.46 | $1.59 | 1.25M |
| Oct 26, 2026 | $1.45 | $1.54 | $1.43 | $1.51 | 1.05M |
| Oct 23, 2026 | $1.58 | $1.585 | $1.43 | $1.44 | 1.05M |
| Oct 22, 2026 | $1.50 | $1.62 | $1.479 | $1.60 | 824.84K |
| Oct 21, 2026 | $1.53 | $1.555 | $1.44 | $1.50 | 1.33M |
| Oct 20, 2026 | $1.45 | $1.55 | $1.4301 | $1.52 | 1.06M |
| Oct 19, 2026 | $1.40 | $1.49 | $1.39 | $1.44 | 575.62K |
| Oct 16, 2026 | $1.49 | $1.51 | $1.40 | $1.40 | 799.53K |
| Oct 15, 2026 | $1.47 | $1.565 | $1.46 | $1.49 | 1.33M |
| Oct 14, 2026 | $1.67 | $1.725 | $1.40 | $1.45 | 1.74M |
| Oct 13, 2026 | $1.86 | $1.86 | $1.625 | $1.70 | 3.33M |
| Oct 12, 2026 | $1.70 | $1.87 | $1.64 | $1.86 | 1.59M |
Latest ADCT news
The latest Smart Investors Daily articles mentioning ADCT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ADCT research
Overview
Company profile and research snapshot.
Company profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Guggenheim | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 4, 2026 | RBC Capital | Sector Perform | — |
| May 5, 2026 | HC Wainwright & Co. | Buy | — |
| May 5, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Nov 4, 2026
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring Transcript
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring November 4, 2026 4:15 PM ESTCompany ParticipantsNicole Riley...
Yahoo · Nov 4, 2026
ADC Therapeutics Reports Strong Lymphoma Responses, Plans Phase III Study
ADC Therapeutics (NYSE:ADCT) outlined new lymphoma data and plans for further studies of its cancer drug ZYNLONTA, while reporting preliminary third-quarter sales of approximately $21 million and an expected cash runway into 2029. The company said Wednesday that five oral presentations and multiple
Yahoo · Nov 4, 2026
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced new and updated data from the ZYNLONTA® (loncastuximab tesirine-lpyl) clinical program will be shared across multiple abstracts, including five oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting taking place December 12–15, 2026, in New Orleans, Louisiana.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
